matched

Clinical investigators are currently exploring ustekinumab, an IL-12 and IL-23 antagonist, for graft vs host disease (GVHD) prophylaxis in matched unrelated donor hematopoietic cell transplantation (HCT) recipients. A phase 2 …

Patient characteristics Baseline characteristics of the study population are shown in Table 1. A total of 8,764 patients were included, of whom 7,725 (88%) received his rATG and 1,039 (12%) …